PMID- 26439384
OWN - NLM
STAT- MEDLINE
DCOM- 20160218
LR  - 20221207
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 127
IP  - 8
DP  - 2015
TI  - Use of oral combination therapy for type 2 diabetes in primary care: Meeting 
      individualized patient goals.
PG  - 808-17
LID - 10.1080/00325481.2015.1085293 [doi]
AB  - The management of type 2 diabetes mellitus (T2DM) by primary care physicians 
      (PCPs) has become increasingly complex due to limitations on consultation time, 
      an increasing array of drug treatment options, and issues of comorbidities and 
      polypharmacy. Diabetes is a progressive condition and treatment with a single 
      glucose-lowering agent can only address limited pathophysiologic targets and does 
      not provide adequate glycemic control in many cases. Consequently, most patients 
      with T2DM will eventually require treatment with multiple glucose-lowering 
      medications. Oral combination therapy in T2DM may be given as multiple-pills, or 
      as single-pill, fixed-dose combinations (FDCs), the latter of which offer 
      convenience, ease of administration, and a reduction in the medication burden. 
      Therefore, FDCs can potentially improve patients' treatment adherence and 
      optimize achievement and maintenance of glycemic targets. However, cost factors 
      also need to be considered. An understanding of the issues associated with the 
      use of combination therapy in T2DM will help PCPs to guide patient-centered 
      decision making and promote the effective management of T2DM.
FAU - Lavernia, Frank
AU  - Lavernia F
AD  - a Internal Medicine and Diabetes, Diabetes and Metabolism, Diabetes Medicine , 
      Coconut Creek , FL , USA.
FAU - Adkins, Sarah E
AU  - Adkins SE
AD  - b Diabetes Endocrine Center at The Diabetes Institute, Athens, OH, USA, College 
      of Pharmacy, Ohio State University , Columbus , OH , USA.
FAU - Shubrook, Jay H
AU  - Shubrook JH
AD  - c Touro University California, College of Osteopathic Medicine , Vallejo , CA , 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151006
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Age Factors
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology/therapy
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin
MH  - Health Behavior
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse 
      effects/economics/*therapeutic use
MH  - Life Style
MH  - Medication Adherence
MH  - Metformin/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Health Care/*methods
MH  - Self Care
OTO - NOTNLM
OT  - Combination drug therapy
OT  - fixed-dose combination
OT  - primary care
OT  - single-pill combination
OT  - type 2 diabetes mellitus
EDAT- 2015/10/07 06:00
MHDA- 2016/02/19 06:00
CRDT- 2015/10/07 06:00
PHST- 2015/10/07 06:00 [entrez]
PHST- 2015/10/07 06:00 [pubmed]
PHST- 2016/02/19 06:00 [medline]
AID - 10.1080/00325481.2015.1085293 [doi]
PST - ppublish
SO  - Postgrad Med. 2015;127(8):808-17. doi: 10.1080/00325481.2015.1085293. Epub 2015 
      Oct 6.